» Articles » PMID: 38167490

High Throughput Intracellular Delivery by Viscoelastic Mechanoporation

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Jan 3
PMID 38167490
Authors
Affiliations
Soon will be listed here.
Abstract

Brief pulses of electric field (electroporation) and/or tensile stress (mechanoporation) have been used to reversibly permeabilize the plasma membrane of mammalian cells and deliver materials to the cytosol. However, electroporation can be harmful to cells, while efficient mechanoporation strategies have not been scalable due to the use of narrow constrictions or needles which are susceptible to clogging. Here we report a high throughput approach to mechanoporation in which the plasma membrane is stretched and reversibly permeabilized by viscoelastic fluid forces within a microfluidic chip without surface contact. Biomolecules are delivered directly to the cytosol within seconds at a throughput exceeding 250 million cells per minute. Viscoelastic mechanoporation is compatible with a variety of biomolecules including proteins, RNA, and CRISPR-Cas9 ribonucleoprotein complexes, as well as a range of cell types including HEK293T cells and primary T cells. Altogether, viscoelastic mechanoporation appears feasible for contact-free permeabilization and delivery of biomolecules to mammalian cells ex vivo.

Citing Articles

Highly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation.

Kim Y, Yun D, Lee J, Jung C, Chung A Nat Commun. 2024; 15(1):8099.

PMID: 39284842 PMC: 11405868. DOI: 10.1038/s41467-024-52493-1.


HiViPore: a highly viable in-flow compression for a one-step cell mechanoporation in microfluidics to induce a free delivery of nano- macro-cargoes.

Maremonti M, Panzetta V, Netti P, Causa F J Nanobiotechnology. 2024; 22(1):441.

PMID: 39068464 PMC: 11282774. DOI: 10.1186/s12951-024-02730-y.

References
1.
Dwarshuis N, Parratt K, Santiago-Miranda A, Roy K . Cells as advanced therapeutics: State-of-the-art, challenges, and opportunities in large scale biomanufacturing of high-quality cells for adoptive immunotherapies. Adv Drug Deliv Rev. 2017; 114:222-239. DOI: 10.1016/j.addr.2017.06.005. View

2.
Lee C, Bishop E, Zhang R, Yu X, Farina E, Yan S . Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis. 2017; 4(2):43-63. PMC: 5609467. DOI: 10.1016/j.gendis.2017.04.001. View

3.
Milone M, ODoherty U . Clinical use of lentiviral vectors. Leukemia. 2018; 32(7):1529-1541. PMC: 6035154. DOI: 10.1038/s41375-018-0106-0. View

4.
Marcucci K, Jadlowsky J, Hwang W, Suhoski-Davis M, Gonzalez V, Kulikovskaya I . Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Mol Ther. 2017; 26(1):269-279. PMC: 5763152. DOI: 10.1016/j.ymthe.2017.10.012. View

5.
Lachelt U, Wagner E . Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond). Chem Rev. 2015; 115(19):11043-78. DOI: 10.1021/cr5006793. View